Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

In Vivo Prepared PICX Chimeric Antigen Receptor T-Cell Therapy for the Treatment of Relapsed/Refractory Multiple Myeloma

NCT07715630 is registered in ClinicalTrials.gov with Chongqing Precision Biotech Co., Ltd as lead sponsor.

NCT NCT07715630
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07715630 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
In Vivo Prepared PICX Chimeric Antigen Receptor T-Cell Therapy for the Treatment of Relapsed/Refractory Multiple Myeloma
Lead sponsor
Chongqing Precision Biotech Co., Ltd
Phase
Phase 1
Overall status
Recruiting
Start date
July 31, 2026
Completion date
July 31, 2028
Enrollment
15 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed or refractory multiple myeloma (rrmm)